OPKO Health: Insider Buying and Sales Concerns Weigh on Valuation After Jefferies Downgrade

OPKO Health (OPK) shares are in focus after CEO Phillip Frost and Frost Gamma Investments Trust bought over $730,000 worth of stock. However, Jefferies issued a downgrade due to cautious sales expectations for Ngenla, OPKO's growth hormone therapy. The recent insider buying sent a positive signal, but the downgrade and uncertainty around Ngenla's future sales weigh on sentiment. The stock's 1-year total shareholder return is -17.09%, and investors wonder if OPKO Health is undervalued or if the market is already factoring in future growth.